Tuesday, April 30, 2024
DM and DAPT
Monday, April 29, 2024
Clubbing
Unfortunately, the art of detailed physical examination is dying. An astute clinician listens to heart and lung sounds and observes other related clinical features simultaneously. Patients with dyspnea may provide an important clue if clubbing is present on the hands.
Clubbing is found to be associated with bronchiectasis, idiopathic pulmonary fibrosis (IPF), lung cancer, and pediatric cyanotic heart disease. Interestingly, patients exclusively with asthma, COPD, or adult-onset hypoxemia usually do not develop clubbing.
Sunday, April 28, 2024
Distant murmurs
- A systolic murmur of peripheral pulmonary stenosis can be audible over the anterior aspects of both lungs.
- A systolic murmur over the back of the chest below or adjacent to the left scapula can be appreciated as severe mitral regurgitation.
Saturday, April 27, 2024
TRALI risk
- Recent surgery (particularly cardiac)
- Cytokine treatment
- Massive blood transfusion
- Active infection (Sepsis/SIRS)
- Low levels of the anti-inflammatory cytokine interleukin-10 (IL-10)
- High C-reactive protein (CRP)
- Liver transplant surgery
- Chronic alcohol abuse
- Shock
- Higher peak airway pressure while being mechanically ventilated
- Current smoking
- Higher interleukin (IL)-8 levels
- Positive fluid balance
- Hematologic malignancy
- A high Acute Physiology and Chronic Health Evaluation II (APACHE II) score
- Recipients of platelet or plasma-containing products
- Female gender
Friday, April 26, 2024
ILO
Thursday, April 25, 2024
Osborn wave
Wednesday, April 24, 2024
Statin and uric acid level
- Losartan
- Atorvastatin
- Fenofibrate
Tuesday, April 23, 2024
Albumin and electrolytes
Monday, April 22, 2024
Unique bactericidal action of metronidazole
Metronidazole is a low molecular weight compound that easily diffuses across the microorganisms' cell membranes. Inside the microbe, metronidazole is reduced by the pyruvate:ferredoxin oxidoreductase (a system in obligate anaerobes). The reduction of metronidazole creates a concentration gradient that drives the uptake of more drugs and promotes the formation of intermediate compounds and free radicals that are toxic to the cell. It causes DNA strand breakage and fatal destabilization of the DNA helix. This process leads to the toxic-intermediate particles and inactive end products.
Sunday, April 21, 2024
SAH and associated symptoms
Saturday, April 20, 2024
Understanding the difference between SRMD and PUD
Friday, April 19, 2024
Vitamin K
Thursday, April 18, 2024
Homan's sign
Wednesday, April 17, 2024
Larva Currens
Tuesday, April 16, 2024
BB and K
Monday, April 15, 2024
Clonidine toxicity
- Depressed mental status
- Miosis
- Depressed respirations
- Bradycardia
- Hypotension
Sunday, April 14, 2024
Myocardial Reperfusion Injury
- Ischemic conditioning
- Glycoprotein IIb/IIIa inhibitors
- Adenosine
- Vasodilators such as nitric oxide (NO), and angiotensin converting enzyme (ACE)
- Ion channel modulation
- Glucose-insulin-potassium solution
- Antineutrophil and anticomplement therapy
- Antioxidant therapy
- Magnesium
- Cyclosporine
- Intravenous MTP-131
- Intravenous sodium nitrite
- Losmapimod
- Inhibitors of delta-protein kinase C
Saturday, April 13, 2024
TLS and choice of fluid in initial phase
Friday, April 12, 2024
Decadron in meningitis
Thursday, April 11, 2024
Nitrates and platelets
Wednesday, April 10, 2024
Listeriosis in pregnancy - treatment
Tuesday, April 9, 2024
abdominal exam
Monday, April 8, 2024
Supraclavicular Subclavian Vein Catheterization: A Forgotten Central Line
- a well-defined insertion landmark (the clavisternomastoid angle);
- a shorter distance from skin to vein;
- a larger target area;
- a straight path to superior vena cava; less proximity to lung; and
- fewer complications of pleural or arterial puncture.
- The supraclavicular approach less often necessitates CPR or tube thoracostomy interruption than the infraclavicular approach.
- A finder or seeker needle (21G and 3.5 cm length) can be used to locate vessel, which minimizes the risk of complications. A finder needle is used mostly when ultrasound is not available during insertion of the internal jugular vein, but it may also help locate the subclavian vein via a supraclavicular approach. The needle should be inserted 1 cm posterior to the sternocleidomastoid and 1 cm cephalad to the clavicle.
Sunday, April 7, 2024
Beta receptors
Saturday, April 6, 2024
EVALI
Friday, April 5, 2024
A case of skin exam
- associated with pharyngitis
- diffuse erythema that blanches with pressure
- sandpaper quality to the skin
- usually starts in the groin and armpits
- a strawberry tongue
- palms and soles are usually spared
- Pastia's lines
Thursday, April 4, 2024
murmurs
- Crescendo (increasing)
- Decrescendo (diminishing)
- Crescendo-decrescendo (increasing-decreasing)
- Plateau (unchanged in intensity)
Wednesday, April 3, 2024
Potassium and kidney stones
Tuesday, April 2, 2024
Exclusion criteria to be eligible for intravenous thrombolysis in acute ischemic stroke
- Patient history
- Clinical
- Hematologic
- Head CT
- Ischemic stroke or severe head trauma in the previous three months
- Previous intracranial hemorrhage
- Intra-axial intracranial neoplasm
- Gastrointestinal malignancy
- Gastrointestinal hemorrhage in the previous 21 days
- Intracranial or intraspinal surgery within the prior three months
- Symptoms suggestive of subarachnoid hemorrhage
- Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg)
- Active internal bleeding
- Presentation consistent with infective endocarditis
- Stroke is known or suspected to be associated with aortic arch dissection
- Acute bleeding diathesis, including but not limited to conditions defined under 'Hematologic'
- Platelet count <100,000/mm3
- Current anticoagulant use with an INR >1.7 or PT >15 seconds or aPTT >40 seconds
- Therapeutic doses of low molecular weight heparin received within 24 hours (eg, to treat VTE and ACS); this exclusion does not apply to prophylactic doses (eg, to prevent VTE)
- Current use (i.e., last dose within 48 hours in a patient with normal renal function) of a direct thrombin inhibitor or direct factor Xa inhibitor with evidence of anticoagulant effect by laboratory tests such as aPTT, INR, ECT, TT, or appropriate factor Xa activity assays
- Evidence of hemorrhage
- Extensive regions of obvious hypodensity consistent with irreversible injury
- Only minor and isolated neurologic signs or rapidly improving symptoms
- Serum glucose <50 mg/dL (<2.8 mmol/L)
- Serious trauma in the previous 14 days
- Major surgery in the previous 14 days
- History of gastrointestinal bleeding (remote) or genitourinary bleeding
- Seizure at the onset of stroke with postictal neurologic impairments
- Pregnancy
- Arterial puncture at a noncompressible site in the previous seven days
- Large (≥10 mm), untreated, unruptured intracranial aneurysm
- Untreated intracranial vascular malformation
- Age >80 years
- Oral anticoagulant use, regardless of INR
- Severe stroke (NIHSS score >25)
- Combination of both previous ischemic stroke and diabetes mellitus